Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 12:15:1395287.
doi: 10.3389/fgene.2024.1395287. eCollection 2024.

Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease

Dominique P Germain  1   2 , Ales Linhart  2
Affiliations
Review

Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease

Dominique P Germain et al. Front Genet. .

Abstract

Fabry disease, a rare X-linked genetic disorder, results from pathogenic variants in GLA, leading to deficient lysosomal α-galactosidase A enzyme activity and multi-organ manifestations. Since 2001, enzyme replacement therapy (ERT), using agalsidase alfa or agalsidase beta, has been the mainstay treatment, albeit with limitations such as rapid clearance and immunogenicity. Pegunigalsidase alfa, a novel PEGylated recombinant alpha-galactosidase, offers promise as an alternative. Produced in plant cells, pegunigalsidase alfa exhibits enhanced stability, prolonged half-life, and reduced immunogenicity due to pegylation. A phase 1/2 clinical trial demonstrated Gb3 clearance from renal capillary endothelial cells and its 48-month extension study revealed notable outcomes in renal function preservation. Three phase 3 clinical trials (BRIDGE, BRIGHT, and BALANCE) have shown favorable efficacy and safety profile, although caution is warranted in interpreting the results of BRIDGE and BRIGHT which lacked control groups. In BALANCE, the pivotal phase 3 trial comparing pegunigalsidase alfa with agalsidase beta, an intention-to-treat analysis of the eGFR decline over 2 years showed that the intergroup difference [95%confidence interval] in the median slope was -0.36 mL/min/1.73 m2/year [-2.44; 1.73]. The confidence interval had a lower limit above the prespecified value of -3 mL/min/1.73 m2/year and included zero. Despite challenges such as occasional hypersensitivity reactions and immune-complex-mediated glomerulonephritis, pegunigalsidase alfa approval by the European Medicines Agency and the Food and Drug Administration represents a significant addition to Fabry disease therapeutic landscape providing an option for patients in whom enzyme replacement therapy with current formulations is poorly tolerated or poorly effective.

Keywords: Fabry disease; PEGylation; agalsidase; non-inferiority trial; renal function.

PubMed Disclaimer

Conflict of interest statement

DG has received speaker’s fees and honoraria from Chiesi, Idorsia, Sanofi, and Takeda. AL has received speaker’s fees and honoraria from Amicus Therapeutics, Chiesi, Sanofi, and Takeda.

Figures

FIGURE 1
FIGURE 1
Current therapeutic landscape in Fabry disease.
See this image and copyright information in PMC

References

    1. Azevedo O., Gago M. F., Miltenberger-Miltenyi G., Sousa N., Cunha D. (2021). Fabry disease therapy: state-of-the-art and current challenges. Int. J. Mol. Sci. 22 (1), 206. 10.3390/ijms22010206 - DOI - PMC - PubMed
    1. Benjamin E. R., Della Valle M. C., Wu X., Katz E., Pruthi F., Bond S., et al. (2017). The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet. Med. 19 (4), 430–438. 10.1038/gim.2016.122 - DOI - PMC - PubMed
    1. Bernat J., Holida M., Longo N., Goker-Alpan O., Wallace E., Deegan P., et al. (2023). eP149: safety and efficacy of pegunigalsidase alfa, every 4 weeks, in Fabry disease: results from the phase 3, open-label, BRIGHT study. Genet. Med. 24, S91–S92. 10.1016/j.gim.2022.01.185 - DOI
    1. Burlina A., Brand E., Hughes D., Kantola I., Kramer J., Nowak A., et al. (2023). An expert consensus on the recommendations for the use of biomarkers in Fabry disease. Mol. Genet. Metab. 139 (2), 107585. 10.1016/j.ymgme.2023.107585 - DOI - PubMed
    1. Chen B. M., Cheng T. L., Roffler S. R. (2021). Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano 15 (9), 14022–14048. 10.1021/acsnano.1c05922 - DOI - PubMed